BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:00 PM
 | 
Oct 04, 2012
 |  BC Extra  |  Company News

NICE reverses prior decision, backs Lucentis in DME

The U.K.'s NICE issued new draft guidance recommending Lucentis ranibizumab from Novartis AG (NYSE:NVS; SIX:NOVN) for diabetic macular edema (DME), but in a population narrower than the one the committee rebuffed last year. NICE now recommends Lucentis...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >